


 Cite this: *RSC Adv.*, 2023, **13**, 25691

Diastereospecific arylation and cascade deconstructive amidation/thioesterification of readily available lactam-fused bromolactones†

 Minh Do, Stella I. Anosike and Timothy K. Beng *

An intrinsic goal when designing synthetic methodology is to identify approaches whereby readily accessible precursors are converted into an array of products, which efficiently tap into new 3D-chemical space. In these studies, readily available bicyclic lactam-bromolactones have been interrogated in several fragment growth protocols by utilizing the halogen and lactone motifs as versatile linchpins for strategic construction of C–C, C–N, C–O, and C–S bonds. Diastereospecific $C(sp^3)$ – $C(sp^2)$ Kumada coupling of sterically imposing [5,5]-bicyclic lactam-bromolactones with several aryl Grignard reagents, under palladium catalysis, furnishes diarylmethane-tethered lactam-lactones in synthetically attractive yields, stereoinvertive fashion, and with a tolerance for many functional groups. When [5,6]-bicyclic lactam-bromolactones, which are prone to β -hydride elimination are employed, efficient arylation is observed only under $Co(acac)_3$ -catalyzed conditions. Importantly, these [5,6]-bicyclic lactam-bromolactones undergo retentive arylation, independent of the transition metal catalyst. A base-mediated cascade deconstructive amidation of the [5,6]-bicyclic lactam-bromolactones with primary aliphatic amines proceeds efficiently to afford epoxide-tethered lactam carboxamides, which bear four contiguous stereocenters. Furthermore, an unusual route to homoallylic thioesters has been uncovered through deconstructive contra-thermodynamic thioesterification of the lactam-fused bromolactone precursors.

 Received 13th July 2023
 Accepted 18th August 2023


 DOI: 10.1039/d3ra04690g
rsc.li/rsc-advances

Introduction

Functionalized γ -lactams bearing contiguous stereocenters (Fig. 1) constitute the core of several alkaloid natural products and pharmaceuticals, including pramanicin (antifungi), omuralide (proteasome inhibitor), and clausenamide (anti-dementia).¹ The γ -lactam topology also presents an ideal platform for systematic scaffolding owing to its latent reactivity and the endless number of transformations it can undergo.²

Notable strategies for the construction of functionalized 2-pyrrolidinones include the ring-opening of aziridines,³ the aza-Heck reaction,⁴ and the use of cascade/multicomponent reactions.⁵ These methodological advances notwithstanding, approaches to the stereocontrolled synthesis of polysubstituted γ -lactams bearing contiguous stereocenters are still underdeveloped.⁶ As the drug development process continues to seek out more sophisticated nitrogen-containing heterocycles with higher degrees of saturation,⁷ the need for divergent methods for the stereocontrolled synthesis and post-diversification of sp^3 -rich 2-pyrrolidinones increases.

One of the key steps in drug discovery is to ‘grow’ fragment hits from potentially any position. Structural diversity is highly desirable given that molecular shape is among the most important factors that dictate the biological effects of molecules. Fragment libraries consisting of a variety of 3D scaffolds are expected to display a wider range of biological activities compared to single scaffold libraries. Within this context, and as part of a program aimed at leveraging the synthetic versatility of the 1,3-azadiene-anhydride reaction,⁸ our group has identified the catalytic halolactonization^{8g,h} of lactam-bearing alkoenoic acids of type 1 (Fig. 2A/B) and subsequent interrogation of



Department of Chemistry, Central Washington University, Ellensburg, WA 98926, USA.
 E-mail: Timothy.beng@cwu.edu

† Electronic supplementary information (ESI) available: Experimental procedures and spectroscopic data. See DOI: <https://doi.org/10.1039/d3ra04690g>






Fig. 2 Proposed plan for the diastereospecific arylation and deconstructive amidation/thioesterification of lactam-halolactones.


the lactam-halolactones (see **2/3**) in fragment growth protocols as an important research objective (Fig. 2C). Specifically, we sought to utilize the halogen and lactone motifs resident in **2/3** as versatile linchpins for strategic late-stage construction of C–C, C–N, C–O, and C–S bonds (see **4–7**). Herein, we describe the efforts toward the realization of our objectives.

Results and discussion


Diastereospecific arylation of lactam-bromolactones

We first sought to explore the amenability of hindered alkyl bromides of type **3** to functional group-tolerant Kumada–Corriu cross-coupling with Grignard reagents.⁹ Such alkyl halides are typically challenging substrates owing to their reluctance to undergo oxidative addition. Furthermore, metal alkyl intermediates tend to induce unproductive β -hydride elimination.¹⁰ Recent methodological advances have however facilitated the formation of carbon–carbon bonds by cross-coupling reactions of less activated alkyl halides and Grignard reagents under palladium catalysis.¹¹ In general, palladium complexes have an exceptional catalytic activity in Kumada cross-coupling, which is mainly attributed to their tendency to undergo a two-electron transfer process as well as to their tolerance for a wide range of functional groups.¹² We initiated studies toward the arylation of lactam-bromolactones with aryl Grignard reagents by

Table 1 Optimization of the arylation of lactam-bromolactone **3a** with phenylmagnesium bromide



conditions A: PhMgBr (1.1 equiv), Pd(PhCN)₂Cl₂ (5 mol%), dppp (5 mol%), 2-MeTHF (0.10 M), rt, 8 h



| Entry | Deviation from conditions A | % yield of 4a (isolated) |
|-----------------|---|---------------------------------|
| 1 | THF as solvent | 80 |
| 2 | 1,4-Dioxane as solvent | 21 |
| 3 | HFIP as solvent | 0 (no reaction) |
| 4 | MeCN as solvent | 74 |
| 5 | DMF as solvent | 0 (no reaction) |
| 6 | DMA as solvent | 0 (no reaction) |
| 7 | Performed at room temp for 18 h | 71 |
| 8 | Performed at 0 °C for 22 h | 66 |
| 9 | Pd(MeCN) ₂ Cl ₂ in place of Pd(PhCN) ₂ Cl ₂ | 81 |
| 10 | Pd(PhCN) ₂ Cl ₂ omitted | 0 (no reaction) |
| 11 | dppp omitted | 0 (no reaction) |
| 12 ^a | dppf (99) in place of dppp (91) | 75 |
| 13 ^a | dppb (94) in place of dppp (91) | 79 |
| 14 ^a | dppm (73) in place of dppp (91) | 47 |
| 15 ^a | rac-BINAP (93) in place of dppp (91) | 68 |
| 16 ^a | Xantphos (108) in place of dppp (91) | 39 |
| 17 | PPPh ₃ in place of dppp | 0 (no reaction) |
| 18 | PCy ₃ in place of dppp | 0 (no reaction) |
| 19 | Conditions B in place of conditions A | 75 |
| 20 | Conditions C in place of conditions A | 62 |
| 21 | Conditions D in place of conditions A | 57 |
| 22 | Conditions E in place of conditions A | 44 |

conditions B

CoCl₂ (5 mol%), TMCD (6 mol%)
2-MeTHF, 0 °C to rt, 12 h

conditions D

Ni(dppe)₂Cl₂ (2.5 mol%)
THF, 23 °C, 6 h

conditions C

Fe(acac)₃ (5 mol%)
THF, TMEDA (10 mol%)
HMTA (5 mol%), 0 °C, 8 h

conditions E


Nickamine (5 mol%)
TMEDA (25 mol%)
THF, 23 °C, 3 h

TMCD = tetramethylcyclohexanediamine

TMEDA = *N,N,N',N'*-tetramethyl-1,2-ethylenediamine

HMTA = hexamethylmethylenetetramine

a: Values in parentheses are the corresponding bite angles in degrees.



benchmarking our optimization efforts for the phenylation of bromolactone **3a** with the reaction conditions described in Table 1.

At the outset, we were concerned about the possibility of reduction of the bromide to bicyclic **8a**. We also recognized that unwanted β -carboxylate elimination could instead lead to the generation of alkenoic acid **1a**. Furthermore, we were concerned about any competing and undesirable nucleophilic addition of the Grignard reagent to the lactone/lactam motifs resident in **3a**. Accordingly, we sought functional group-tolerant conditions




that would not only minimize β -carboxylate elimination, but also facilitate oxidative addition, transmetalation, and reductive elimination. Ultimately, 2-methyltetrahydrofuran (2-MeTHF) emerged as the preferred reaction medium (entries 1–6). The reaction proceeds slowly at 0 °C (entry 8). We have found that $\text{Pd}(\text{MeCN})_2\text{Cl}_2$ is slightly less efficient than the bulky $\text{Pd}(\text{PhCN})_2\text{Cl}_2$ precatalyst (entry 9). No background cyclization reaction is observed in the absence of the palladium catalyst (entry 10). Knowing that the bite angle of the ligand can have a dramatic effect on the efficiency of cross-couplings, several ligands were evaluated (entries 12–18). Resounding success was mostly achieved when *bis*-1,2-diphenylphosphinopropane (dppp) was utilized. The results indicate that smaller or larger bite angles adversely affect the coupling. The respective bite angles are provided in parentheses. Other reaction conditions known to promote Kumada cross-couplings with alkyl halides were surveyed (entries 19–22). The reaction worked well under cobalt-catalyzed conditions (entry 19). Presumably, the TMCD ligand helped to suppress β -carboxylate elimination. In these cases, the mass balance was mostly accounted for by recovered starting material, reduction product **8a**, and β -carboxylate elimination product **1a**. The spectroscopic data for byproducts **8a** and **1a** are available in the ESI.† Under the optimized conditions (*i.e.*, conditions A), diarylmethane-tethered lactam-lactone **4a** was obtained in good yield.

The scope of the transformation with respect to the lactam-bromolactone has been surveyed (Scheme 1, see **4a–v**). Knowing that the nature of the nitrogen substituent present on a nitrogen heterocycle can have a dramatic effect on its biological activity¹³ and reactivity, the effect of the *N*-substituent on the arylation was first explored. Encouragingly, *N*-alkyl-substituted lactam-bromolactones are competent substrates for the coupling (see **4a–d**). The successful construction of arylated lactam-lactones harboring the *N*-phenethyl group (see **4e–g** and **4i/j**) is noteworthy given that the phenethyl group is often employed as a precursor to the indolizidine/quinolizidine scaffold. A readily removable benzyl group is well-tolerated (see **4h**).

When the phenyl group on the reactive center is replaced by an electron-deficient *p*-chlorophenyl or *p*-fluorophenyl group, the efficacy of the transformation is not compromised (see **4k–t**). Similarly, the deployment of an electron-rich *p*-methoxyphenyl or *p*-tolyl group leads to efficient phenylation (see **4u/v**). It is commendable that aryl halide-bearing substrates couple exclusively at the benzylic site (see **4g/i/k–v**), without complications arising from aryl–aryl coupling. *N*-Arylated γ -lactam-bromolactones underwent productive cross-coupling with phenylmagnesium bromide (see **4m/u/v**), which is noteworthy since *N*-aryl γ -lactams are embedded in several pharmacologically pertinent targets.¹⁴ The incorporation of a fluorinated moiety into organic molecules generally increases the solubility, lipophilicity and metabolic stability of the parent molecules, thus, explaining why ~25% of existing preclinical drugs and 40% of agrochemicals contain at least one fluorine atom.¹⁵ It is therefore noteworthy that fluorinated products **4l–t** are obtainable in satisfactory yields.

The scope of the arylation with respect to the Grignard reagent has been explored, *albeit* briefly (Scheme 2). Electron-



Isolated yields are reported in all cases.

PMP = *para*-methoxyphenyl; PCP = *para*-chlorophenyl

PFP = *para*-fluorophenyl

Performed on 1.0 to 5.0 mmol scale using 1 to 5 mL 2-MeTHF.

Diastereomeric ratios were determined by GC-MS and


^1H (^{19}F where applicable) NMR analyses of the crude products.

Relative configurations were established through NOE analyses.

Scheme 1 Diastereospecific Kumada cross-coupling of various lactam-bromolactones with phenylmagnesium bromide.

deficient and electron-rich aryl Grignard reagents are competent coupling partners (**4w** vs. **4x**), suggesting that the coupling is less sensitive to its electronic environment. An *ortho*-





Scheme 2 Kumada cross-coupling of lactam-bromolactones with electronically diverse Grignard reagents.


substituted aryl Grignard reagent is marginally tolerated as exemplified through the synthesis of diarylmethane **4z2**. A sterically imposing 2-naphthyl group can be installed using the corresponding Grignard reagent, but the efficiency is unsurprisingly modest (see **4z3**). Indeed, our luck runs out when even more imposing 1-naphthylmagnesium bromide is employed as no coupling takes place (see **4z4**). Additionally, no coupling is observed when highly π -deficient 2-pyridylmagnesium bromide is employed as the coupling partner (see **4z5**). This indicates that transmetalation step is critical and probably rate-limiting. Our studies have revealed that the arylation reaction takes place stereoinvertively (as judged by NOESY) as the diarylmethane-tethered lactam-lactones are obtained in impeccable diastereoselectivities (see **4k–4z3**). NOE correlations are shown in the ESI for compounds **4w–z**. For example, clear NOEs are observed between protons H_a and H_b as well as between protons H_b and H_c (see **4w** for the numbering).

The palladium-catalyzed Kumada coupling discussed so far is widely understood to proceed through insertion of the Pd(0) catalyst into the C–Br bond of the benzylic bromide.^{10c} Subsequent transmetalation with the Grignard reagent forms a hetero-organometallic complex, which undergoes isomerization and concomitant reductive elimination to furnish the

diarylmethane-tethered lactam-lactone, with regeneration of the Pd(0) catalyst.

The amenability of [5,6]-bicyclic lactam-bromolactones of type **2** to cross-coupling with PhMgBr has been briefly investigated. To our delight, satisfactory cross-coupling was observed under the Co-catalyzed conditions described in Scheme 3. NOESY data revealed that diastereoretentive coupling too place (NOEs were observed between the α -amino and α -alkoxy protons resident in **5a** and **5c**). The PN ligand proved to be critical in suppressing undesirable β -hydride elimination. The strategic deployment of Co(acac)₃ as the precatalyst is noteworthy given its relative stability and ease of storage. Although Kumada-type cross-couplings with cobalt have been extensively studied,¹⁶ sterically imposing halides of type **2** tend to react slowly. It is worth mentioning that using the reaction conditions developed for coupling of **3**, the reaction of **2b** (R = *tert*-Bu) with PhMgBr afforded mainly the β -hydride elimination product (*i.e.*, **9**) in 77% yield. The small amount of **5b** that was formed in this case also displayed a preference for stereo-invertive arylation. This result indicates that the mode of attack of the aryl Grignard reagent is substrate-dependent rather than catalyst-dependent. Thus, whereas [5,6]-bicyclic lactam-bromolactones of type **2** undergo invertive arylation, the corresponding [5,5]-bicyclic lactam-bromolactones of type **3** display a preference for retentive arylation.

Regarding the mechanistic underpinnings of this Co-catalyzed cross-coupling with PhMgBr, congruent with literature reports,^{16a} we tentatively postulate that reduction of the Co(acac)₃ pre-catalyst by PhMgBr furnishes the ‘active’ catalytic species (see **10**, Fig. 3). The low-valent cobalt species (*i.e.*, **10**) undergoes single-electron transfer (SET) with lactam-bromolactone **2a** to furnish secondary radical **12**, (*via* the dissociation of radical-anion **11**). Subsequent transmetalation



Scheme 3 Cobalt-catalyzed cross-coupling of lactam-bromolactones of type **2** with phenylmagnesium bromide.







Fig. 3 Tentative mechanism for Co-catalyzed diastereospecific arylation of lactam-bromolactones of type 2.

between PhMgBr and cationic cobalt species **13** delivers intermediate **14**, which unites with radical **12** to furnish complex **15**. Concomitant reductive elimination of **15** gives rise to coupling product **5a** with regeneration of active catalyst **10**. The diastereoselective formation of **5a** is presumably governed by steric effects. Indeed, when the two diastereomeric secondary bromides *anti*-**2a** and *syn*-**2a** (with respect to the bromine-bearing stereocenter) were reacted separately with phenylmagnesium bromide using the reaction conditions described in Scheme 3, the same stereoisomer of product **5a** was obtained, indicating a diastereo-convergence of the cross-coupling. Such diastereo-convergent cross-couplings on 6-membered rings organic halides have previously been observed.^{16c} It is worth reiterating that in the proposed mechanism, the true active catalyst as well as the order of the elementary steps are yet to be fully established.

Diastereoselective synthesis of epoxide-tethered lactam carboxamides

The carboxamide motif is prevalent in natural products (*e.g.*, penicillin), (bio)polymers (*e.g.*, proteins and nylon), ligands, fragrances, pharmaceuticals, and agrochemicals.¹⁷ We reasoned that a strategy, which merges a functionalized γ -lactam, a highly substituted epoxide, and a carboxamide motif, would likely enhance the potential for the discovery of new small molecules with medicinal value. The preparation of carboxamides from carboxylic acids and amines is a high priority reaction, particularly from the standpoint of atom economy.¹⁸ However, it is marred by the high energy barrier for dehydration of a stable ammonium carboxylate.¹⁹ As such, the synthesis of carboxamides is traditionally achieved through the *N*-acylation of amines using moisture-sensitive acid chlorides¹⁹ or anhydrides.²⁰ However, these protocols suffer from limited reagent stability and shelf life, hazardous reagent preparation, and their corrosive nature. Meanwhile, the use of coupling agents such as DCC,²¹ EDC,²² CDI,²³ PyBOP,²⁴ BOP,²⁵ HBTU,²⁶ and HATU (ref. 27) to achieve amidation results in acute safety hazards due to




Scheme 4 Construction of γ -lactam carboxamides from lactam-bromolactones of type 2.

their explosive and allergenic natures. Sustainable approaches to epoxide-tethered γ -lactam carboxamides that do not rely on the aforementioned problematic reagents are therefore desirable. Intrinsic to our design was the prospect of employing cascade reactions to access epoxide-tethered γ -lactam carboxamides, given that the former are inherently step and atom-economical. Cascade reactions often lead to a reduction in the amount of waste and in the number of purification steps.²⁸ Pleasingly, after surveying several bases and solvents, we found that fused bicyclic lactam-bromolactones of type 2 undergo efficient cascade deconstructive epoxy-amidation to afford the epoxylactam carboxamides depicted in Scheme 4. Nucleophilic addition of the amine to the lactone is accompanied by ring-opening and intramolecular backside attack of the displaced alkoxide on the organic bromide. Concomitant elimination of the bromide leaving group furnishes the epoxide.

Deconstructive thioesterification of lactam-bromolactones

Functionalized thioesters are useful building blocks in organic synthesis and biochemistry.^{29,30} Conventional routes for the preparation of thioesters involve the reaction of acyl chlorides with metal thiolates,³¹ the condensation of carboxylic acids with thiols, the displacement of halides with thiocarboxylates,^{32,33} the Mitsunobu reaction of alcohols with thioacetic acids,³⁴ and carbonylation reactions in the presence of thiols.³⁵ The conversion of more reactive thioesters to less reactive esters is readily achievable.³⁶ In contrast, due to the high leaving group ability of thiolates, there is little to no driving force for the conversion from esters/lactones to thioesters/thiolactones under typical conditions. Specifically, to the best of our knowledge, there are no known methods for the synthesis of S-





Scheme 5 Construction of γ -lactam thioesters from lactam-bromolactones of type 2.

aryl thioesters from lactones. Efforts to overcome these methodological limitations have led to the discovery that lactam-bromolactones of type 2 are amenable to contrathermodynamic cascade deconstructive aryl thioesterification under the conditions described in Scheme 5. The detailed mechanistic underpinnings of the transformation are currently under investigation.

Conclusions

In summary, readily available lactam-bromolactones have been interrogated in three different fragment growth protocols. Diastereoretentive Pd-catalyzed Kumada cross-coupling of hindered benzylic bromides of type 3 with several aryl Grignard reagents has led to the synthesis of diarylmethane-tethered lactam-lactones such as 4, in synthetically attractive yields. Conversely, secondary nonbenzylic organic bromides of type 2, which are highly susceptible to β -hydride elimination undergo arylation under Co-catalyzed conditions to afford the corresponding products (*i.e.*, 5) with complete inversion of configuration at the leaving group-bearing carbon. The protocol tolerates a variety of functional groups, which bodes well for late-stage modification. Furthermore, we have developed mild conditions for cascade deconstructive amidation and contrathermodynamic thioesterification of lactam bromolactones such as 2. The epoxy-amidation reaction proceeds efficiently to afford pharmaceutically pertinent lactam carboxamides, which bear four contiguous stereocenters. Meanwhile, the thioesterification reaction furnishes lactam-tethered homoallylic thioesters in an unusual manner. It is anticipated that the structural diversity accomplished in these studies would endow it with some practical advantages over some existing diversity-oriented synthesis methodologies given that fragment libraries

consisting of a variety of 3D scaffolds continue to display a wider range of biological activities compared to single scaffold libraries.

Author contributions

M. D. – investigation, data curation, validation; S. I. A. – investigation, methodology; T. K. B. – conceptualization, project administration, data curation, methodology, supervision, writing – original draft, internal funding acquisition.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

We are grateful to Central Washington University for financial support through startup funds. The school of graduate studies and Provost DenBeste are thanked for research fellowships to S. I. A. and T. K. B.

Notes and references

- (a) R. H. Feling, G. O. Buchanan, T. J. Mincer, C. A. Kauffman, P. R. Jensen and W. Fenical, *Angew. Chem., Int. Ed.*, 2003, **42**, 355–357; (b) L. R. Reddy, P. Saravanan and E. J. Corey, *J. Am. Chem. Soc.*, 2004, **126**, 6230–6231; (c) R. De Vreese and M. D'Hooghe, *Beilstein J. Org. Chem.*, 2012, **8**, 398–402; (d) X. Zheng, X.-J. Dai, H.-Q. Yuan, C.-X. Ye, J. Ma and P.-Q. Huang, *Angew. Chem., Int. Ed.*, 2013, **52**, 3494; (e) K.-Z. Hu, J. Ma, S. Qiu, X. Zheng and P.-Q. Huang, *J. Org. Chem.*, 2013, **78**, 1790; (f) S. P. Lathrop and T. Rovis, *Chem. Sci.*, 2013, **4**, 1668; (g) N. Armanino and E. M. Carreira, *J. Am. Chem. Soc.*, 2013, **135**, 6814; (h) K. L. Kimmel, J. D. Weaver, M. Lee and J. A. Ellman, *J. Am. Chem. Soc.*, 2012, **134**, 9058; (i) N. Satoh, S. Yokoshima and T. Fukuyama, *Org. Lett.*, 2011, **13**, 3028; (j) R. A. Shenvi and E. J. Corey, *J. Am. Chem. Soc.*, 2009, **131**, 5746; (k) T. B. Poulsen, G. Dickmeiss, J. Overgaard and K. A. Jørgensen, *Angew. Chem., Int. Ed.*, 2008, **47**, 4687; (l) G. Ma, H. Nguyen and D. Romo, *Org. Lett.*, 2007, **9**, 2143; (m) D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T. H. Chao, S. T. Neuteboom, P. Richardson, M. A. Palladino and K. C. Anderson, *Cancer Cell*, 2005, **8**, 407; (n) S. Fustero, M. García de la Torre, J. F. Sanz Cervera, C. Ramírez de Arellano, J. Piera and A. Simón, *Org. Lett.*, 2002, **4**, 3651; (o) A. G. M. Barrett, J. Head, M. L. Smith, N. S. Stock, A. J. P. White and D. J. Williams, *J. Org. Chem.*, 1999, **64**, 6005; (p) E. J. Corey and W.-D. Z. Li, *Chem. Pharm. Bull.*, 1999, **47**, 1; (q) C. W. G. Fishwick, R. J. Foster and R. E. Carr, *Tetrahedron Lett.*, 1996, **37**, 3915.
- (a) C. Gomez, M. Gicquel, J.-C. Carry, L. Schio, P. Retailleau, A. Voituriez and A. Marinetti, *J. Org. Chem.*, 2013, **78**, 1488; (b) K.-J. Xiao, A.-E. Wang and P.-Q. Huang, *Angew. Chem.*,



Int. Ed., 2012, **51**, 8314; (c) C. Shao, H.-J. Yu, N.-Y. Wu, P. Tian, R. Wang, C.-G. Feng and G.-Q. Lin, *Org. Lett.*, 2011, **13**, 788; (d) K.-J. Xiao, J.-M. Luo, K.-Y. Ye, Y. Wang and P.-Q. Huang, *Angew. Chem., Int. Ed.*, 2010, **49**, 3037; (e) G. Chouhan and H. Alper, *Org. Lett.*, 2008, **10**, 4987; (f) A. Agosti, S. Britto and P. Renaud, *Org. Lett.*, 2008, **10**, 1417; (g) A. Gheorghe, M. Schulte and O. Reiser, *J. Org. Chem.*, 2006, **71**, 2173; (h) T. Okino, Y. Hoashi, T. Furukawa, X. Xu and Y. Takemoto, *J. Am. Chem. Soc.*, 2005, **127**, 119; (i) S. Madan, P. Milano, D. B. Eddings and R. E. Gawley, *J. Org. Chem.*, 2005, **70**, 3066.

3 L. I. Kas'yan, V. A. Pal'chikov and Y. S. Bondarenko, *Russ. J. Org. Chem.*, 2011, **47**, 1609–1652.

4 S. A. Shuler, G. Yin, S. B. Krause, C. M. Vesper and D. A. Watson, *J. Am. Chem. Soc.*, 2016, **138**, 13830–13833.

5 (a) N. T. Burdzhiev and E. R. Stanoeva, *Z. Naturforsch., B: J. Chem. Sci.*, 2008, **63**, 313–320; (b) N. Castagnoli, Jr, *J. Org. Chem.*, 1969, **34**, 3187–3189.

6 (a) N. Kanbayashi, K. Takenaka, T. Okamura and K. Onitsuka, *Angew. Chem., Int. Ed.*, 2013, **52**, 4897; (b) M. Hatano and T. Nishimura, *Angew. Chem., Int. Ed.*, 2015, **54**, 10949; (c) J. L. Panger and S. E. Denmark, *Org. Lett.*, 2020, **22**, 2501; (d) K. Ashida, Y. Hoshimoto, N. Tohnai, D. E. Scott, M. Ohashi, H. Imaizumi, Y. Tsuchiya and S. Ogoshi, *J. Am. Chem. Soc.*, 2020, **142**, 1594; (e) H. Qian, S. Sun, W. Zhao and J. Sun, *Chem. Sci.*, 2020, **56**, 11295; (f) P. V. Ramachandran and T. E. Burghardt, *Chem.-Eur. J.*, 2005, **11**, 4387.

7 E. Vitaku, D. T. Smith and J. T. Njardarson, *J. Med. Chem.*, 2014, **57**, 10257–10274.

8 (a) H. Braunstein, S. Langevin, M. Khim, J. Adamson, K. Hovenkotter, L. Kotlarz, B. Mansker and T. K. Beng, *Org. Biomol. Chem.*, 2016, **14**, 8864–8872; (b) T. K. Beng and A. Moreno, *New J. Chem.*, 2020, **44**, 4257–4261; (c) T. K. Beng, M. Bauder, M. J. Rodriguez and A. Moreno, *New J. Chem.*, 2018, **42**, 16451–16455; (d) K. Hovenkotter, H. Braunstein, S. Langevin and T. K. Beng, *Org. Biomol. Chem.*, 2017, **15**, 1217–1221; (e) T. K. Beng and A. Moreno, *RSC Adv.*, 2020, **10**, 8805–8809; (f) J. Garcia, J. Eichwald, J. Zesiger and T. K. Beng, *RSC Adv.*, 2022, **12**, 309–318; (g) T. K. Beng, M. Rodriguez and C. Borg, *RSC Adv.*, 2022, **12**, 17617–17620; (h) T. K. Beng, C. Borg and M. Rodriguez, *RSC Adv.*, 2022, **12**, 28685–28691.

9 In 1986, the (dppf)Pd(0)-catalyzed cross-coupling reaction of a secondary alkyl iodide with Grignard reagents was reported: (a) P. L. Castle and D. A. Widdowson, *Tetrahedron Lett.*, 1986, **27**, 6013, It has since been revealed that the reaction instead afforded reduction or β -elimination products rather than the coupling products; (b) K. Yuan and W. J. Scott, *Tetrahedron Lett.*, 1989, **30**, 4779.

10 (a) X. Hu, *Chimia, International Journal for Chemistry*, 2010, **64**, 231–234; (b) I. Yonova, A. Johnson, C. Osborne and C. Moore, *Angew. Chem.*, 2014, **53**, 2422–2427; (c) C. E. I. Knappke and A. Jacobi von Wangenheim, *Chem. Soc. Rev.*, 2011, **40**, 4948–4962.

11 (a) E. Galardon, S. Ramdeehul, J. M. Brown, A. Cowley, K. K. Hii and A. Jutand, *Angew. Chem.*, 2002, **41**, 1760–1763; (b) G. Molander and B. Canturk, *Angew. Chem.*, 2009, **48**, 9240–9261; (c) S. E. Denmark and C. S. Regens, *Acc. Chem. Res.*, 2008, **41**, 1486–1499; (d) A. Lopez-Perez, J. Adrio and J. C. Carretero, *Org. Lett.*, 2009, **11**, 5514–5517; (e) A. H. Cherney, N. T. Kadunce and S. E. Reisman, *Chem. Rev.*, 2015, **115**, 9587–9652; (f) Z. Xi, B. Liu and W. Chen, *J. Org. Chem.*, 2008, **73**, 3954–3957; (g) A. Joshi-Pangu, C. Y. Wang and M. R. Biscoe, *J. Am. Chem. Soc.*, 2011, **133**, 8478–8481; (h) Q. Zhou, K. M. Cobb, T. Tan and M. P. Watson, *J. Am. Chem. Soc.*, 2016, **138**, 12057–12060.

12 (a) M. Fernández-Rodríguez and J. Hartwig, *J. Org. Chem.*, 2009, **74**, 1663–1672; (b) A. Kumar, G. Kumar Rao, S. Kumar and A. Singh, *Organometallics*, 2014, **33**, 2921–2943.

13 T. K. Beng and R. E. Gawley, *J. Am. Chem. Soc.*, 2010, **132**, 12216.

14 (a) X. Qiao, D. L. Cheney, R. S. Alexander, A. M. Smallwood, S. R. King, K. He, A. R. Rendina, J. M. Luettgen, R. M. Knabb, R. R. Wexler and P. Y. S. Lam, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 4118–4123; (b) M. A. Larsen, E. T. Hennessy, M. C. Deem, Y. Lam, J. Sauri and A. C. Sather, *J. Am. Chem. Soc.*, 2020, **142**, 726–732.

15 T. Liang, C. N. Neumann and T. Ritter, *Angew. Chem., Int. Ed.*, 2013, **52**, 8214–8264.

16 (a) A. Guérinot and J. Cossy, *Acc. Chem. Res.*, 2020, **53**, 1351–1363; (b) G. Cahiez and A. Moyeux, *Chem. Rev.*, 2010, **110**, 1435–1462; (c) J. A. Killion, W. T. Darrow, M. R. Brennan, C. A. Leahy and A. R. Fout, *Organometallics*, 2022, **41**, 1769–1776; (d) C. Anderson, V. Ferey, M. Daumas, P. Bernardelli and J. Cossy, *Org. Lett.*, 2019, **21**, 6241; (e) T. Iwasaki, H. Takagawa, S. P. Singh, H. Kuniyasu and N. Kambe, *J. Am. Chem. Soc.*, 2013, **135**, 9604; (f) W. Affo, H. Ohmiya, T. Fujioka, Y. Ikeda, T. Nakamura, H. Yorimitsu, K. Oshima, Y. Imamura, T. Mizuta and K. Miyoshi, *J. Am. Chem. Soc.*, 2006, **128**, 8068; (g) G. Kiefer, H. Vrubel, R. Scopelliti and K. Severin, *Eur. J. Inorg. Chem.*, 2013, **28**, 4916–4921; (h) F. Kreyenschmidt and K. Koszinowski, *Chem.-Eur. J.*, 2018, **24**, 1168; (i) F. Kreyenschmidt, S. E. Meurer and K. Koszinowski, *Chem.-Eur. J.*, 2019, **25**, 5912.

17 (a) J. S. Carey, D. Laffan, C. Thomson and M. T. Williams, *Org. Biomol. Chem.*, 2006, **4**, 2337–2347; (b) J. Pitzer and K. J. Steiner, *Biotechnol.*, 2016, **235**, 32–46.

18 (a) D. J. C. Constable, P. J. Dunn, J. D. Hayler, G. R. Humphrey, J. L. Leazer Jr, R. J. Linderman, K. Lorenz, J. Manley, B. A. Pearlman, A. Wells, A. Zaks and T. Y. Zhang, *Green Chem.*, 2007, **9**, 411–420; (b) M. C. Bryan, P. J. Dunn, D. Entwistle, F. Gallou, S. G. Koenig, J. D. Hayler, M. R. Hickey, S. Hughes, M. E. Kopach, G. Moine, P. Richardson, F. Roschangar, A. Steven and F. Weiberth, *J. Green Chem.*, 2018, **20**, 5082–5103.

19 (a) H. Charville, D. Jackson, G. Hodges and A. Whiting, *Chem. Commun.*, 2010, **46**, 1813–1823; (b) L. J. Goossen, D. M. Ohlmann and P. P. Lange, *Synthesis*, 2009, **209**, 160–164; (c) B. S. Jursic and Z. Zdravkovski, *Synth. Commun.*, 1993, **23**, 2761–2770.

20 L. Zhang, X. J. Wang, J. Wang, N. Grinberg, D. Krishnamurthy and C. H. Senanayake, *Tetrahedron Lett.*, 2009, **50**, 2964–2966.

21 L. E. Coleman, J. F. Bork and H. Dunn, *J. Org. Chem.*, 1959, **24**, 135–136; J. C. Sheehan and G. P. Hess, *J. Am. Chem. Soc.*, 1955, **77**, 1067–1068.

22 N. Goyal, *Synlett*, 2010, **20**, 335–336.

23 R. Paul and G. W. Anderson, *J. Am. Chem. Soc.*, 1960, **82**, 4596–4600.

24 V. Dourtoglou, B. Gross, V. Lambropoulou and C. Zioudrou, *Synthesis*, 1984, **19**, 572–574.

25 L. A. Carpino, *J. Am. Chem. Soc.*, 1993, **115**, 4397–4398.

26 (a) J. W. Bode and L. J. Goossen, *Top. Organomet. Chem.*, 2012, **44**, 13–33; (b) H. Lundberg, F. Tinnis, N. Selander and H. Adolfsson, *Chem. Soc. Rev.*, 2014, **43**, 2714–2742.

27 F. Ye, Y. Ge, A. Spannenberg, H. Neumann and M. Beller, *Nat. Commun.*, 2020, **11**, 5383.

28 D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang and J. Woolsey, *Nucleic Acids Res.*, 2006, **34**, D668–D672.

29 (a) A. L. Lehninger, D. L. Nelson and M. M. Cox, *Principles of Biochemistry*, Worth Publishing, New York, 2002; (b) C. de Duve, *Am. Sci.*, 1995, **83**, 428–437.

30 For reviews of sulfur-containing drugs, see: (a) E. A. Ilardi, E. Vitaku and J. T. Njardarson, *J. Med. Chem.*, 2014, **57**, 2832–2842; (b) B. R. Beno, K. S. Yeung, M. D. Bartberger, L. D. Pennington and N. A. Meanwell, *J. Med. Chem.*, 2015, **58**, 4383–4438; (c) K. A. Scott and J. T. Njardarson, *Top. Curr. Chem.*, 2018, **376**, 1–34; (d) M. Feng, B. Tang, S. H. Liang and X. Jiang, *Curr. Top. Med. Chem.*, 2016, **16**, 1200–1216; (e) N. Wang, P. Saidhareddy and X. Jiang, *Nat. Prod. Rep.*, 2020, **37**, 246–275.

31 S. Patai, *Chemistry of Functional Groups: Carboxylic Acids and Esters*, Wiley, New York, 1969.

32 S. Fujiwara and N. Kambe, *Top. Curr. Chem.*, 2005, **251**, 87–140.

33 Y. Mori and M. Seki, *Org. Synth.*, 2007, **84**, 285.

34 R. Volante, *Tetrahedron Lett.*, 1981, **22**, 3119–3122.

35 V. Hirschbeck, P. H. Gehrtz and I. Fleischer, *Chem.-Eur. J.*, 2018, **24**, 7092–7107.

36 (a) W. K. Chan, S. Masamune and G. O. Spessard, *Org. Synth.*, 1983, **61**, 48; (b) N. A. McGrath and R. T. Raines, *Acc. Chem. Res.*, 2011, **44**, 752–761.

